Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights
News provided by
Share this article
SAN DIEGO, Feb. 25, 2021 /PRNewswire/
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, today announced recent company highlights and financial results for the fourth quarter and full year ended December 31, 2020. Over the last several months we achieved key clinical milestones, which provided the momentum for our successful raise of over $100 million. Together, these events have enabled us to accelerate the execution of our clinical programs and expand our pipeline to other relevant cancer indications, said Dr. Mark Erlander, chief executive officer of Cardiff Oncology. Data from our lead KRAS-mutated metastatic color
Data Bridge Market Research recently published a report, titled,
“Pharmacy Automation Market 2021”: It offers in-depth analysis of the industry size, share, major segments, and different geographic regions, forecast for the next seven years, key market players, and premium industry trends. It also focuses on the key drivers, opportunities and industry challenges.A comprehensive report gives details about historic data, present market trends, future product environment, marketing strategies, technological innovation, upcoming technologies, emerging trends or opportunities, and the technical progress in the related industry. Pharmacy Automation market report aids in achieving a sustainable growth in the market, by providing a well-versed, specific and most relevant product and market information. The market drivers and restraints have been explained using SWOT analysis. Business intelligence has been applied to generate this market report which is a vital aspect when it comes t